Co-Diagnostics, Inc.

Equities

CODX

US1897631057

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
1.26 ^USD	+4.13%		+7.69%	-5.26%

Apr. 12	Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event	CI
Apr. 04	Co-Diagnostics, Inc. Appoints Executive Appointments	CI

Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:06 pm EDT

Co-Diagnostics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.991473 million compared to USD 34.22 million a year ago. Revenue was USD 6.81 million compared to USD 34.22 million a year ago.

Net loss was USD 35.33 million compared to USD 14.24 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 0.45 a year ago. Diluted loss per share from continuing operations was USD 1.2 compared to USD 0.45 a year ago.

Latest news about Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event	Apr. 12	CI
Co-Diagnostics, Inc. Appoints Executive Appointments	Apr. 04	CI
Co-Diagnostics, Inc. Appoints Richard Abbott as President	Mar. 15	CI
Transcript : Co-Diagnostics, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.	Mar. 14	CI
Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Co-Diagnostics Gets Approval From India's Central Drugs Standard Control Organization For Manufacturing, Sale of Influenza Multiplex Test	Mar. 07	MT
Co-Diagnostics Submits PCR COVID-19 Test and PCR Pro Instrument for FDA Review	Dec. 27	MT
Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform	Dec. 27	DJ
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro	Dec. 27	CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $3 From $2, Maintains Neutral Rating	Nov. 13	MT
Transcript : Co-Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $2.5M	Nov. 09	MT
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.	Nov. 09	CI
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from S&P Global BMI Index	23-09-18	CI
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer	23-08-29	CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $3, Keeps Neutral Rating	23-08-14	MT
Transcript : Co-Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.	23-08-10	CI
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q2 Revenue $0.2M	23-08-10	MT
Co-Diagnostics Wins Gates Foundation Grants for Tuberculosis, HPV Tests	23-07-18	MT
Co-Diagnostics, Inc. Announces Recent Grant Awards	23-07-18	CI
Co-Diagnostics Receives $1.2 Million in New Funds From National Institutes of Health	23-07-13	MT

Chart Co-Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.26 USD

Average target price

2.5 USD

Spread / Average Target

+98.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
CO-DIAGNOSTICS, INC.	-5.26%	39.39M
SARTORIUS AG	-15.34%	18.77B
QUIDELORTHO CORPORATION	-41.10%	2.9B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+24.02%	1.97B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	+8.62%	1.82B
BIOTAGE AB	+26.63%	1.25B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-7.74%	1.06B
CONTEC MEDICAL SYSTEMS CO.,LTD	-18.61%	936M
REVENIO GROUP OYJ	-1.03%	770M
VAREX IMAGING CORPORATION	-23.76%	639M

Medical Diagnostic & Testing Equipment